Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0B8SC
|
||||
| Former ID |
DIB001878
|
||||
| Drug Name |
BOF-4272
|
||||
| Synonyms |
Rac-8-[3-Methoxy-4-(phenylsulfinyl)phenyl]pyrazolo[1,5-a]-1,3,5-triazin-4-ol sodium salt hydrate
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Gout [ICD9: 274.00274.1274.8274.9; ICD10:M10] | Discontinued in Phase 2 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H14N4O3S
|
||||
| Canonical SMILES |
COC1=C(C=CC(=C1)C2=CNN3C2=NC=NC3=O)S(=O)C4=CC=CC=C4
|
||||
| InChI |
1S/C18H14N4O3S/c1-25-15-9-12(14-10-21-22-17(14)19-11-20-18(22)23)7-8-16(15)26(24)13-5-3-2-4-6-13/h2-11,21H,1H3
|
||||
| InChIKey |
RAUZDCRFPSDXRB-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 117411-27-5
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Xanthine dehydrogenase/oxidase | Target Info | Inhibitor | [2], [3] | |
| BioCyc Pathway | Purine nucleotides degradation | ||||
| Urate biosynthesis/inosine 5'-phosphate degradation | |||||
| Guanosine nucleotides degradation | |||||
| Adenosine nucleotides degradation | |||||
| Retinoate biosynthesis II | |||||
| KEGG Pathway | Purine metabolism | ||||
| Caffeine metabolism | |||||
| Drug metabolism - other enzymes | |||||
| Metabolic pathways | |||||
| Peroxisome | |||||
| PANTHER Pathway | Adenine and hypoxanthine salvage pathway | ||||
| Purine metabolism | |||||
| PathWhiz Pathway | Caffeine Metabolism | ||||
| Purine Metabolism | |||||
| Reactome | Purine catabolism | ||||
| WikiPathways | Oxidative Stress | ||||
| Effects of Nitric Oxide | |||||
| Metabolism of nucleotides | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002649) | ||||
| REF 2 | Enantioselective uptake of BOF-4272, a xanthine oxidase inhibitor with a chiral sulfoxide, by isolated rat hepatocytes. Yakugaku Zasshi. 2001 Dec;121(12):989-94. | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.